MCID: PNC015
MIFTS: 34

Pancreatic Acinar Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Acinar Cell Adenocarcinoma

MalaCards integrated aliases for Pancreatic Acinar Cell Adenocarcinoma:

Name: Pancreatic Acinar Cell Adenocarcinoma 12 15
Acinar Cell Adenocarcinoma of the Pancreas 73
Pancreatic Acinar Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5742
NCIt 50 C7977
UMLS 73 C0279661

Summaries for Pancreatic Acinar Cell Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that has material basis in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.

MalaCards based summary : Pancreatic Acinar Cell Adenocarcinoma, also known as acinar cell adenocarcinoma of the pancreas, is related to acinar cell carcinoma and acinar cell carcinoma of pancreas, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreatic Acinar Cell Adenocarcinoma is BCL10 (B Cell CLL/Lymphoma 10). The drugs Capecitabine and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pancreatic Acinar Cell Adenocarcinoma

Diseases related to Pancreatic Acinar Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 22)
# Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma 30.4 AFP BCL10 CHGA
2 acinar cell carcinoma of pancreas 11.2
3 pancreatitis 10.8
4 panniculitis 10.1
5 orofaciodigital syndrome viii 10.1 AFP BCL10
6 adenocarcinoma 10.1
7 rh isoimmunization 10.0 AFP BCL10
8 hepatitis 9.9
9 islet cell tumor 9.9
10 conn's syndrome 9.9
11 neuroendocrine tumor 9.9
12 acute pancreatitis 9.9
13 peritonitis 9.9
14 adult teratoma 9.9 AFP CHGA
15 sclerosing hepatic carcinoma 9.9 AFP CHGA
16 liver sarcoma 9.8 AFP CHGA
17 pancreatoblastoma 9.8 AFP CHGA
18 testicular germ cell tumor 9.8 AFP BCL10
19 pancreatic cystadenocarcinoma 9.8 AFP CHGA
20 endodermal sinus tumor 9.7 AFP CHGA
21 tubular adenocarcinoma 9.6 AFP CHGA
22 cell type cancer 9.2 AFP CHGA

Graphical network of the top 20 diseases related to Pancreatic Acinar Cell Adenocarcinoma:



Diseases related to Pancreatic Acinar Cell Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Acinar Cell Adenocarcinoma

UMLS symptoms related to Pancreatic Acinar Cell Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.28 AFP CELA1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.28 CELA1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.28 CELA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.28 AFP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.28 AFP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.28 CELA1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.28 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.28 AFP

Drugs & Therapeutics for Pancreatic Acinar Cell Adenocarcinoma

Drugs for Pancreatic Acinar Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Not Applicable 154361-50-9 60953
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
4
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
5
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
6
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
8 pancreatin Phase 3,Phase 2,Phase 1
9 Micronutrients Phase 3,Phase 2,Phase 1
10 Trace Elements Phase 3,Phase 2,Phase 1
11 Vitamin B Complex Phase 3,Phase 2,Phase 1
12 Vitamins Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
14 Antidotes Phase 3,Phase 2,Phase 1
15 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Protective Agents Phase 3,Phase 2,Phase 1
17 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
19 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
21 Calcium, Dietary Phase 3,Phase 2,Phase 1
22
Erlotinib Hydrochloride Phase 3,Phase 1 183319-69-9 176871
23 Folate Nutraceutical Phase 3,Phase 2,Phase 1
24 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
25
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
26
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
27
Irinotecan Approved, Investigational Phase 2,Phase 1,Not Applicable 97682-44-5, 100286-90-6 60838
28
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
29
Oxaliplatin Approved, Investigational Phase 2,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
30
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
31
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
32
Metformin Approved Phase 2,Early Phase 1 657-24-9 14219 4091
33
nivolumab Approved Phase 2 946414-94-4
34
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
35
Ifosfamide Approved Phase 2 3778-73-2 3690
36 Bryostatin 1 Investigational Phase 2 83314-01-6
37
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
38 topoisomerase I inhibitors Phase 2,Phase 1,Not Applicable
39 Adjuvants, Immunologic Phase 2
40 Albumin-Bound Paclitaxel Phase 2,Phase 1
41 Gastrointestinal Agents Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 2,Phase 1,Not Applicable
43 Angiogenesis Inhibitors Phase 2
44 Angiogenesis Modulating Agents Phase 2
45 Anti-Bacterial Agents Phase 2,Phase 1
46 Antibiotics, Antitubercular Phase 2,Phase 1
47 Antimitotic Agents Phase 2,Phase 1
48 Antineoplastic Agents, Phytogenic Phase 2,Phase 1,Not Applicable
49 Hypoglycemic Agents Phase 2,Early Phase 1
50 Antibodies Phase 2

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
2 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
3 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Completed NCT00416793 Phase 2 bortezomib;carboplatin
4 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
5 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
6 Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Completed NCT00397787 Phase 2 sunitinib malate
7 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Completed NCT00085371 Phase 2 triapine
8 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
9 Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Completed NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
10 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
11 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
12 Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation;selinexor
13 Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Active, not recruiting NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
14 Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer Terminated NCT00967291 Phase 2 ifosfamide;mitomycin C
15 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
16 Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
17 Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Active, not recruiting NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
18 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
19 Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT00669734 Phase 1
20 GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT00878163 Phase 1 Erlotinib Hydrochloride;Gemcitabine Hydrochloride;Vismodegib
21 Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
22 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
23 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Suspended NCT01537107 Phase 1 vismodegib;sirolimus
24 Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Terminated NCT01739439 Phase 1 gemcitabine hydrochloride
25 Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Withdrawn NCT01741597 Phase 1
26 Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Completed NCT01821612 Not Applicable oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
27 Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Recruiting NCT02153450 Early Phase 1 metformin hydrochloride

Search NIH Clinical Center for Pancreatic Acinar Cell Adenocarcinoma

Genetic Tests for Pancreatic Acinar Cell Adenocarcinoma

Anatomical Context for Pancreatic Acinar Cell Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Acinar Cell Adenocarcinoma:

41
Pancreas, Liver, Lung, Skin

Publications for Pancreatic Acinar Cell Adenocarcinoma

Articles related to Pancreatic Acinar Cell Adenocarcinoma:

(show top 50) (show all 73)
# Title Authors Year
1
BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. ( 29506751 )
2018
2
<i>EGFR</i> amplification induces sensitivity to anti<i>EGFR</i> therapy in pancreatic acinar cell carcinoma. ( 29666669 )
2018
3
Bouveret syndrome and pancreatic acinar cell carcinoma. ( 28135730 )
2017
4
Liver Metastases in Pancreatic Acinar Cell Carcinoma Treated with Selective Internal Radiation Therapy with Y-90 Resin Microspheres. ( 29158927 )
2017
5
Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. ( 28588779 )
2017
6
Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration. ( 28921102 )
2017
7
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. ( 29259370 )
2017
8
Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. ( 28671770 )
2017
9
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. ( 29052123 )
2017
10
Murine Pancreatic Acinar Cell Carcinoma Growth Kinetics Are Independent of Dietary Vitamin D Deficiency or Supplementation. ( 28702373 )
2017
11
Metastatic pancreatic acinar cell carcinoma in a younger male with marked AFP production: A potential pitfall on fine needle aspiration biopsy. ( 27634114 )
2016
12
KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. ( 27290644 )
2016
13
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. ( 27857025 )
2016
14
Pancreatic panniculitis as a paraneoplastic phenomenon of a pancreatic acinar cell carcinoma. ( 27112929 )
2016
15
A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients. ( 27660464 )
2016
16
TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. ( 26586531 )
2016
17
Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. ( 27165126 )
2016
18
Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report. ( 27860444 )
2016
19
Pancreatic Acinar Cell Carcinoma. ( 27403122 )
2016
20
Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. ( 25959244 )
2015
21
Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. ( 26600777 )
2015
22
Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. ( 26628966 )
2015
23
Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. ( 25569665 )
2015
24
Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA. ( 25805480 )
2015
25
Sudden disappearance of the blood flow in a case of pancreatic acinar cell carcinoma. ( 25400180 )
2014
26
&amp;quot;Chronic&amp;quot; metastatic pancreatic acinar cell carcinoma. ( 24075523 )
2013
27
Comparison of pancreatic acinar cell carcinoma and adenocarcinoma using multidetector-row computed tomography. ( 24039366 )
2013
28
BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. ( 23530562 )
2013
29
The CT findings of pancreatic acinar cell carcinoma in five cases. ( 23465983 )
2013
30
Clinical and CT imaging features of pancreatic acinar cell carcinoma. ( 23358813 )
2013
31
The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma. ( 22228907 )
2012
32
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature. ( 21961498 )
2012
33
Functional pancreatic acinar cell carcinoma extending into the main pancreatic duct and splenic vein. ( 20703831 )
2012
34
Endoscopic ultrasound image of alpha-fetoprotein-producing pancreatic acinar cell carcinoma. ( 21944950 )
2012
35
Pancreatic acinar cell carcinoma. ( 21982066 )
2012
36
Spontaneous rupture of a pancreatic acinar cell carcinoma presenting as an acute abdomen. ( 22543229 )
2012
37
Intraductal polypoid growth variant of pancreatic acinar cell carcinoma metastasizing to the intrahepatic bile duct 6 years after surgery: a case report and literature review. ( 22487469 )
2012
38
Multimodal treatment of hepatic metastasis in the form of a bile duct tumor thrombus from pancreatic acinar cell carcinoma: case report of successful resection after chemoradiation therapy. ( 22949891 )
2012
39
Image of the month: Cystic variant of pancreatic acinar cell carcinoma. ( 22582413 )
2012
40
Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3). ( 22687839 )
2012
41
Expression of claudin-5 in canine pancreatic acinar cell carcinoma - An immunohistochemical study. ( 21354944 )
2011
42
An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. ( 21475719 )
2011
43
PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. ( 20890270 )
2011
44
Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. ( 21572398 )
2011
45
Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. ( 20182344 )
2010
46
A case of pancreatic acinar cell carcinoma metastatic to skin. ( 21234254 )
2010
47
Pancreatic acinar cell carcinoma: a multi-institutional study. ( 19495891 )
2009
48
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. ( 19666905 )
2009
49
The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. ( 19066953 )
2009
50
Clinical challenges and images in GI: image 3. Pancreatic acinar cell carcinoma with subcutaneous fat necrosis. ( 18789332 )
2008

Variations for Pancreatic Acinar Cell Adenocarcinoma

Expression for Pancreatic Acinar Cell Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Acinar Cell Adenocarcinoma.

Pathways for Pancreatic Acinar Cell Adenocarcinoma

GO Terms for Pancreatic Acinar Cell Adenocarcinoma

Cellular components related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.92 AFP CEL CELA1 CHGA

Sources for Pancreatic Acinar Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....